Expert Prof Paresh Vyas and host Dr Enrica Orsini delve into the latest AML treatment developments in this podcast. They discuss new drug targets, new therapies in clinics, the impact of the new treatment on aging patients & more. Find it on #EHACampus: ehaedu.org/unplugged_AML_…

T cell lymphoma tx is a major unmet need in #oncology It’s astonishing that 4 all the progress made in understanding the pathogenesis (and classification) of PTCL, treatment options are still so limited. To CHOP or not to CHOP Slide by Dr. S Horwitz Memorial Sloan Kettering Cancer Center #SH23

The crazy case of a #T-cell ALL that switched to acute myeloid leukemia shortly after #CART-cellTherapy targeting #CD7. #Myeloid switch could be a new escape mechanism of leukemia under the pressure of targeting CD7. haematologica.org/article/view/h…

Bookmark: mSMART guidelines for myeloma are now available to download as PowerPoint slides. For over 15 years mSMART guidelines have been used by thousands of clinicians around the world. Shaji Kumar Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 Mayo Myeloma #MedTwitter msmart.org/mm-treatment-g…

How I treat refractory and relapsed acute myeloid leukemia loom.ly/mH07I1U #HowITreat #myeloidneoplasia

How I treat von Willebrand disorders in older adults ow.ly/GcsP50QslWU #geriatrichematology #thrombosisandhemostasis

Original Article: Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease nej.md/3GBKq8I #Hematology

Congratulations to the University Hospital of North Tees North Tees and Hartlepool NHS Foundation Trust who were presented with the Myeloma UK Clinical Service Excellence (CSEP) award today! 🧡

Our haematology team has been recognised with a national award for the care given to patients with incurable cancer after being presented today with the Myeloma UK Clinical Service Excellence Programme (CSEP) Award. nth.nhs.uk/news/cancer-te…

The escalation of conflict in #Myanmar, including Rakhine State, is deeply concerning. We call for ▶️all actors to ensure the protection of civilians ▶️the end to arms flow to the military ▶️unhindered humanitarian access 🇦🇺🇨🇦🇪🇺🇰🇷🇲🇹🇳🇿🇳🇴🇨🇭🇬🇧🇺🇸 Joint Statement 👇

#ISTH2024 ard.bmj.com/content/82/10/…

🌟 EOSINOPHILIA - Evaluation *SM - Systemic Mastocytosis From William's Manual Of Hematology. 10ed

📢The official opening session of the IACH Meeting ⬇️ iachlive.cme-congresses.com starts now in Hall A ⬇️ iachlive.cme-congresses.com/hall-a/ Mohamad Mohty

I estimate over 100,000 person years of life saved in myeloma due to the FDA accelerated approval pathway, without factoring recent approval of 3 bispecifics.

For #ASH24. Active myeloma drugs in one table with mechanism of action. Bookmark! Black font — Approved drugs Blue font — Investigational #ASH24VR

#ASH24 ASH #mmsm Suggested treatment approach for AL amyloidosis Suzanne Lentzsch, MD, PhD

This was a very practical poster at #ASH24, looking at prolonged dosing intervals of teclistamab, which is very relevant as dosing of tec (and other bispecific antibodies) moves to q4 week (or even longer intervals). New recommendation: if dosing interval ≤62 days, no need to

Primary large B-cell lymphomas of immune-privileged sites ow.ly/Sbr150Uv2Pc #lymphoidneoplasia

MGUS: With increased testing and with mass spectrometry to detect monoclonal (M) proteins, we are increasingly finding smaller and smaller monoclonal gammoapthies of near zero significance. We need to interpret testing for monoclonal proteins correctly: 1) Low risk MGUS (see

My Updated Myeloma Treatment Algorithms. #ASCO25 Bookmark! Presented at COMy. 1) Newly Diagnosed myeloma transplant ineligible.